Efficacy News and Research

RSS

EpiCept fourth quarter revenue decreases to $0.2 million

EpiCept Corporation today announced operating and financial results for the fourth quarter and full year ended December 31, 2011, and provided an update on the Company's key business initiatives.

29 Feb 2012

FDA accepts Tau Therapeutics' mibefradil IND for treatment of cancer

Tau Therapeutics LLC, a pharmaceutical company developing T-type calcium channel inhibitors for the treatment of solid tumors, announced today that its investigational new drug application (IND 109196) for its novel drug mibefradil has been accepted by the Food and Drug Administration (FDA).

28 Feb 2012

Baxter commences CD34+ stem cell phase III trial in CMI

Baxter International Inc. announced today that it has initiated a phase III pivotal clinical trial to evaluate the efficacy and safety of adult autologous (an individual's own) CD34+ stem cells to increase exercise capacity in patients with chronic myocardial ischemia (CMI).

From Baxter International Inc. 28 Feb 2012

ICON announces acquisition of PriceSpective

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the acquisition of PriceSpective LLC, a global leader in value strategy consulting.

28 Feb 2012

DBV receives FDA Fast Track Designation for Viaskin Peanut clinical development program

DBV Technologies announced today that it has received "Fast Track Designation" for the Clinical Development Program of its Viaskin Peanut, a product designed for the treatment by Epicutaneous Immunotherapy (EPIT) of patients with peanut allergy.

28 Feb 2012

Dompé enters definitive agreement to acquire Anabasis

Dompé, one of Italy's leading biopharmaceutical companies, announced today that it has entered into a definitive agreement to acquire 100% of Anabasis Srl, a privately held Italian research and development biopharmaceutical company, focused on ocular diseases.

28 Feb 2012

BioConnections, Yissum to commercialize kits that detect MDR and XDR infections

Yissum, the research and development company of the Hebrew University of Jerusalem, had signed a licensing agreement with BioConnections, a UK based microbiology company, for the commercialization of kits that enables immediate detection of all multidrug resistant (MDR) and of any extremely drug resistant (XDR) infections.

27 Feb 2012

ATI commences European trial of neurostimulation system for migraine

Autonomic Technologies, Inc. (ATI), the developer of a novel miniaturized implantable stimulator for severe headaches, today announced initiation of a study in Europe to evaluate the safety and efficacy of the company's investigational neurostimulation system for the treatment of high frequency, high disability migraine.

27 Feb 2012

Chronic pain patients at high-risk for comorbid substance abuse benefit from 3-week program

Research presented at the American Academy of Pain Medicine's 28th Annual Meeting shows that substance use education incorporated into a cognitive behavioral rehabilitation programming is effective to improve pain and function for the chronic pain patient at high-risk for comorbid substance abuse.

27 Feb 2012

News briefs from featured presentations at Cardiology 2012

Pediatric cardiology researchers and clinicians from almost 50 centers from across the U.S. and around the world are gathering at the Cardiology 2012 Conference sponsored by The Children's Hospital of Philadelphia on Feb. 22-26 in Orlando, Fla.

27 Feb 2012

FDA panel votes in favor of earlier rejected anti-obesity drug Qnexa

Qnexa took a step closer to approval on Wednesday, when outside advisers to the U.S. Food and Drug Administration voted 20-to-2 in favor of approval. The panel also recommended the company conduct a study to scrutinize even more closely any risk of heart problems. That study may be required after the drug is approved. Should the FDA ask for further data on heart risks before any approval, it would delay Qnexa's launch further.

26 Feb 2012

Evolutionary forces encourage diversity in the active surfaces of venomous toxins

For snakes, spiders, and other venomous creatures, the "business end," or active part, of a toxin is the area on the surface of a protein that is most likely to undergo rapid evolution in response to environmental constraints, say researchers from Ben Gurion University in Israel.

24 Feb 2012

SANUWAVE, CAN-med Healthcare enter distribution agreement for dermaPACE device

SANUWAVE Health, Inc. has entered into a two-year exclusive distribution agreement with CAN-med Healthcare, a division of IMP Group Limited, to distribute the Company's dermaPACE device throughout Canada.

24 Feb 2012

Forest Laboratories' Colobreathe dry powder inhaler receives EMA approval

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer, today announced that it has been granted European Medicines Agency (EMA) approval to market Colobreathe dry powder colistimethate sodium for inhalation for treating cystic fibrosis patients aged 6 years and older with chronic lung infection caused by P. aeruginosa.

24 Feb 2012

Ipsen, Active Biotech report data from tasquinimod Phase II study on CRPC

Active Biotech's and Ipsen's castrate resistant prostate cancer project, TASQ, will be presented at the 27th Annual EAU Congress held in Paris on 24-28 February 2012.

24 Feb 2012

Physical activity keeps workers mentally fit

Obesity can be a dangerous risk to our physical health, but according to a Tel Aviv University researcher, avoiding the gym can also take a toll on our mental health, leading to depression and greater burnout rates at work.

24 Feb 2012

EMA accepts MAA filing of Genzyme's teriflunomide for MS

Genzyme, a Sanofi company, announced today the European Medicines Agency (EMA) has accepted the filing of the marketing authorization application (MAA) for once-daily oral teriflunomide for the treatment of relapsing forms of multiple sclerosis (MS).

24 Feb 2012

Pfizer responds to CDC’S ACIP discussion related to use of Prevnar 13 in adults over 50

Pfizer Inc. issued the following statement in response to today's discussion by the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP) regarding the use of Prevnar 13 (Pneumococcal 13-valent Conjugate Vaccine)in adults 50 years of age and older.

23 Feb 2012

Intravenous ibuprofen: A key addition to perioperative pain management

Hendersonville Medical Center today announced that anesthesiologist Peter B. Kroll, M.D., has published an article in the January issue of peer-reviewed medical journal Pain Management.

23 Feb 2012

Medivir reports net sales of SEK 698.6M for fiscal 2011

Today, Medivir AB, a research-based specialty pharmaceutical company focused on infectious diseases, is publishing its Interim Report for the period 1 January - 31 December and its operational report for the fourth quarter of 2011.

23 Feb 2012